{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T14:10:55Z","timestamp":1784124655777,"version":"3.55.0"},"reference-count":0,"publisher":"AVES YAYINCILIK A.\u015e.","issue":"1","license":[{"start":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T00:00:00Z","timestamp":1768521600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Archives of Rheumatology"],"abstract":"<jats:p>Background\/Aims: Glucocorticoids (GCs) and disease-modifying antirheumatic drugs (DMARDs) are commonly used drugs in the treatment of immunoglobulin G4\u2013related disease (IgG4-RD). However, no broad consensus is available on their intervention effects. Therefore, the efficacy and safety of different medication protocols in the treatment of IgG4-RD were assessed in this systematic review and network meta-analysis.\r\nMaterials and Methods: This study was conducted following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses. RStudio and Stata 15.1 were used for data analysis.\r\nResults: The results showed that in terms of improvement of remission rates, GCs + DMARDs had the strongest overall efficacy [surface under the cumulative ranking curve (SUCRA) = 82.9%], and DMARDs were the most effective within 12 months during follow-up (SUCRA = 82.5%), while GCs + DMARDs were the most effective over 12 months during follow-up (SUCRA = 83.2%). In terms of reduction of relapse rates, the overall efficacy of GCs + DMARDs was the strongest (SUCRA = 83.5%), and GCs + DMARDs performed the best both within and over 12 months during follow-up. The adverse reaction rates were 38.9%, 5.3%, and 33.3%, respectively, among patients treated with GCs + DMARDs, DMARDs, and GCs.\r\nConclusion: The GCs + DMARDs are recommended for short-term improvement of remission rates and reduction of relapse rates, as well as for achieving long-term efficacy.\r\nCite this article as: Liu Y, Fu X, Zhang Y, et al. Comparison of efficacy and safety of different medication protocols in patients with immunoglobulin G4\u2013related disease based on follow-up time: A systematic review and network meta-analysis. ArchRheumatol. 2026;41(1):3-13.<\/jats:p>","DOI":"10.5152\/archrheumatol.2026.25136","type":"journal-article","created":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T18:29:57Z","timestamp":1768933797000},"page":"3-13","source":"Crossref","is-referenced-by-count":2,"title":["Comparison of Efficacy and Safety of Different Medication Protocols in Patients with Immunoglobulin G4\u2013Related Disease Based on Follow-up Time: A Systematic Review and Network Meta-analysis"],"prefix":"10.5152","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-5819-7264","authenticated-orcid":false,"given":"Yanwen","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3367-2132","authenticated-orcid":false,"given":"Xianghui","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-3742-9188","authenticated-orcid":false,"given":"Youqun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-4884-9065","authenticated-orcid":false,"given":"Yan","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2764-970X","authenticated-orcid":false,"given":"Junfeng","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4807-0406","authenticated-orcid":false,"given":"Zhaohui","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8391-4945","authenticated-orcid":false,"given":"Ping","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5578-0142","authenticated-orcid":false,"given":"Kui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3111","published-online":{"date-parts":[[2026,1,16]]},"container-title":["Archives of Rheumatology"],"original-title":[],"link":[{"URL":"https:\/\/www.archivesofrheumatology.org\/index.php\/pub\/article\/download\/1532\/2741","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.archivesofrheumatology.org\/index.php\/pub\/article\/download\/1532\/2741","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T18:30:06Z","timestamp":1769538606000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.archivesofrheumatology.org\/index.php\/pub\/article\/view\/1532"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,16]]},"references-count":0,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1,20]]}},"URL":"https:\/\/doi.org\/10.5152\/archrheumatol.2026.25136","relation":{},"ISSN":["2618-6500"],"issn-type":[{"value":"2618-6500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,16]]}}}